In a nutshell This phase 3 trial aims to evaluate the safety and effectiveness of alogliptin (Nesina) in pediatric patients with type 2 diabetes. The main outcome to be investigated is the effect on blood glucose control after 26 weeks of treatment. The details Managing blood glucose levels is key in the treatment of type 2 diabetes....
Read MoreIn a nutshell This phase 2 trial aims to compare the safety and effectiveness of receiving Neo-Kidney Augment™ (NKA) using two different approaches following diagnosis with chronic kidney disease (CKD) The main outcome to be investigated is kidney function by measuring glomerular filtration rate (eGFR) 12 months following NKA...
Read More
In a nutshell This study investigated the safety and effectiveness of SGLT2 inhibitors, in addition to insulin, in people with type 1 diabetes (T1D). It determined that SGLT2 inhibitors were safe and effective. Some background SGLT2 is a protein in the kidneys that is important in controlling blood glucose levels. It allows glucose to re-enter the...
Read MoreIn a nutshell These guidelines presented recommendations for lifestyle management in people with diabetes. It was determined that diabetes self-management education and support (DSMES), nutrition therapy, physical activity, stopping smoking, and caring for emotional wellbeing are needed. Some background Lifestyle management is an important part of...
Read More
In a nutshell This study investigated whether a combination of high-intensity interval training (HIIT) exercise plus post-exercise protein could reduce the risk of cardiovascular disease in people with type 2 diabetes (T2D). It was determined that HIIT reduced the stiffness and thickness of arterial walls and reduced the resting heart rate. However,...
Read More
In a nutshell This study investigated the effects of diet and physical activity in preventing or delaying type 2 diabetes (T2D), and its complications, in people at high risk of developing T2D. It was determined that diet and/or physical activity reduces or delays the development of T2D in these people. Some background The number of people with...
Read More
In a nutshell This study examined the effectiveness and safety of two forms of insulin glargine in people with type 2 diabetes (T2D). It determined that both forms reduced HbA1c (measures average blood glucose over the last 3 months), but the more concentrated form was less likely to cause hypoglycemia (dangerously low blood glucose). Some background...
Read More
In a nutshell These guidelines presented recommendations for the management of diabetes in pregnancy. It was concluded that counseling before pregnancy, appropriate care during pregnancy, and follow-up after delivery is needed. Some background Diabetes in pregnancy is increasing in the United States. Most of this is due to gestational diabetes...
Read MoreIn a nutshell This study investigated the effectiveness and safety of ertugliflozin (Steglatro) plus sitagliptin (Januvia), compared to either drug used alone, in people with type 2 diabetes (T2D). It was determined that the combination was better at controlling blood glucose levels, without increasing the risk of side effects. Some background...
Read More
In a nutshell This study determined whether or not a moderate intake of wine would be overall beneficial for patients with well-controlled type 2 diabetes. The authors concluded that initiating the drinking of wine, as part of a healthy diet, modestly decreases heart-disease risk. Some background Moderate consumption of alcohol (particularly wine)...
Read More
After three hurricanes, flooding, fires and mudslides, and now severe cold and snow in the Deep South and throughout the country, the US has had its share of emergencies. Are you prepared? For people who rely on oxygen, who are on dialysis, have diabetes or other serious conditions, it is time to think about putting together some of the essentials. What...
Read MoreIn a nutshell This study compared the effectiveness of the three long-acting GLP-1RAs: once-weekly exenatide (Byetta), dulaglutide (Trulicity), and albiglutide (Tanzeum). The authors concluded that after six months all three treatments equally reduced HbA1c. Some background Glucagon-like peptide-1 receptor agonists...
Read More
